Comarch S.A.

Comarch S.A. is a global IT company headquartered in Kraków, Poland. The company provides advanced IT solutions for multiple industries including telecommunications, finance, healthcare, and public administration. Founded in 1993, Comarch has grown to become a significant player in the IT industry, offering a wide range of software products and services that support business operations and improve efficiency for organizations around the world.

Ryvu Terapeutics

Ryvu Therapeutics is a clinical-stage drug discovery and development company focused on novel small-molecule therapies that address emerging targets in oncology. Internally discovered pipeline candidates at Ryvu use diverse therapeutic mechanisms driven by emerging knowledge of cancer biology, including small molecules directed at kinases, synthetic lethality, and immuno-oncology targets. Ryvu’s most advanced program is RVU120, a selective CDK8/CDK19 kinase inhibitor with the potential to treat hematological malignancies and solid tumors. RVU120 is currently in Phase II development (i) as a monotherapy for the treatment of patients with relapsed/refractory acute myeloid leukemia (r/r AML) and high-risk myelodysplastic syndromes (HR-MDS) – the RIVER-52 study, (ii) in combination with venetoclax for the treatment of patients with r/r AML – the RIVER-81 study, and (iii) as a monotherapy for the treatment of patients with lower risk myelodysplastic syndromes (LR-MDS) – the REMARK study. SEL24 (MEN1703) is a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group that is expected to start a Phase II study in diffuse large B-cell lymphoma (DLBCL) in Q4 2024. RVU305, a potentially best-in-class PRMT5 inhibitor aiming to treat multiple solid tumors, is currently undergoing IND/CTA-enabling studies. Ryvu Therapeutics has signed 11 partnering and licensing deals with global companies, including BioNTech and Exelixis. The company was founded in 2007 and is headquartered in Kraków, Poland. Ryvu is listed on the Warsaw Stock Exchange and is a component of the mWIG40 index. For more information, please see www.ryvu.com.

Selvita S.A.

Selvita provides comprehensive services in the areas of drug discovery, regulatory research, and research and development on behalf of pharmaceutical, biotechnology, chemical and agrochemical companies from around the world. Selvita assists its clients with innovative small-molecule drug discovery work, from molecular target validation to clinical candidate selection. We offer clients support that is optimally tailored to their needs - it can be limited to single research areas (e.g., chemical synthesis, bioassays), through any combination of these, to a fully integrated project covering all stages of early drug discovery. In addition, Selvita is an international contract research organization that provides world-class pharmaceutical services in drug testing and bioanalytical analysis. We perform services at every stage of the drug discovery process, from method development and validation, stability studies, to routine quality control testing, in accordance with GMP/GLP principles.

Uniwersytet Jagielloński

Jagiellonian University is Poland's oldest and finest institution of higher learning. Founded in 1364 by Casimir the Great and renovated in 1400 by Queen Jadwiga and King Wladyslaw Jagiello, the University skillfully combines centuries-old tradition with modernity. Jagiellonian University was founded in 1364 in Krakow, Poland. It currently has 16 faculties, three of which make up the Collegium Medicum. In accordance with the principles of the Bologna Process, studies are divided into three degrees: bachelor's, master's and doctoral. All faculties are governed by the European ECTS credit point system, which makes it possible to combine studies at UJ with those at other foreign universities. The University also offers postgraduate studies.

Narodowy Instytut Onkologii im. Marii Skłodowskiej - Curie - Państwowy Instytut Badawczy Oddział w K

The Maria Sklodowska-Curie National Institute of Oncology - National Research Institute Krakow Branch accepts patients diagnosed with cancer or its suspicion, conducting preliminary and in-depth diagnostics and comprehensive treatment: surgery, radiation (radiotherapy) and systemic treatment, including personalized treatment based on, among other things, molecular diagnostics. The Krakow Branch of the Institute also conducts scientific and research, preventive and didactic activities in the field of diagnosis and treatment of malignant tumors, and deals with oncological epidemiology. The institute's highly qualified team of specialists and scientists carries out the mission set many years ago: "We excel to treat as well as possible." The types of cancers that the specialists of the Krakow branch of the Institute cover with diagnosis and treatment are: breast, large intestine, prostate, ovary, cervix and corpus uteri, vagina, vulva, kidney, adrenal gland, bladder, urethra, pancreas, liver (primary and metastatic lesions), testis and penis, lung, stomach, spleen, thyroid, as well as malignant skin tumors (carcinoma and melanoma), malignant mesenchymal tumors (sarcomas): reproductive organs and soft tissues, brain tumors, and malignant proliferations of lymphoid tissue and marrow: non-Hodgkin's lymphoma and Hodgkin's lymphoma, chronic lymphocytic leukemia and acute lymphoblastic leukemia, multiple myeloma.

Sano – Centre for Computational Medicine

Research institute dedicated to the advancement of computational medicine inspired to digitally transform healthcare by unlocking the value of data and enabling the data-driven health decisions. Sano conducts research in frames of the following five thematic groups: Health Informatics, Computer Vision Data Science, Clinical Data Science, Extreme-scale Data and Computing, Personal Health Data Science. Offers advanced expertise in: AI, machine learning, computer vision, neuroimaging, neural networks and deep learning, personal health & clinical data science, health informatics, high performance computing & cloud computing, big data analysis, mHealth, in-silico experiments, biomedical engineering and technology etc. Looking for collaboration with medical researchers (cancer, NCDs, brain tumors, Alzheimer's, Parkinson's, diabetes, cardiovascular, obesity, drug repurposing, pharmacy and more), hospitals, patient organizations, SMEs - eHealth interoperability solution providers etc.

AstraZeneca

AstraZeneca is one of the largest biopharmaceutical companies in the world, providing cutting-edge medicines for diseases that challenge modern medicine. We have been present in Poland for more than 30 years. In 1991, the Polish representative office of Astra was established, which changed its name to Astra Pharmaceuticals Poland Sp. z o.o. in 1998. After the company's consolidation with Zeneca Polska Sp. z o.o., AstraZeneca Pharma Poland Sp. z o.o., still operating today, was established. Since its inception, we have continually emphasized development. Research and development activities are key, as clinical trials are an important pillar of AstraZeneca's innovation. In 2011, a global Clinical Research Operations Center was established in Warsaw as the first in this part of Europe and one of six such R&D centers in the world. Since 2020, the Warsaw facility has held the status of a Research and Development Center. The company's scientific and technological progress would not have been possible without cooperation with the public, measures

Epam Systems (Poland) Sp. z o.o.

As a global leader in software development services with over 30 years of experience, EPAM works for renowned Life Sciences and Healthcare companies, including 8 of the 10 largest pharma enterprises, 4 of the 10 top healthcare ISVs and 4 of 5 top US health plans, as well as many other pharmaceutical, biotechnology, medical device, scientific instrumentation, healthcare provider, and payer firms. EPAM’s dedicated Life Sciences and Healthcare industry solutions practice accumulates scientific informatics, pharmaceutical and healthcare industry expertise and helps deliver value to EPAM clients through our industry-tailored approach. Most of our engagements in the industry are driven by referrals and successfully last for multiple years. We build relationships with our clients on the principle of openness, transparency and collaboration and are flexible in the way we contract and provide services. Our experience in this industry accounts for a significant portion of our revenue, as of FY 2023 it is around 11%. EPAM has developed more than 2,500 custom solutions for our Life Sciences and Healthcare clients. Our portfolio includes award-winning, mission-critical enterprise, research, and public-facing software. We have outstanding experience in implementing custom solutions for all aspects of drug discovery and possess a unique combination of technical and domain knowledge skills in scientific informatics, including cheminformatics, bioinformatics, development informatics, clinical informatics, and medical informatics, as well as experience building regulatory-compliant software within multiple industries and including 21 CFR Part 11 and GxP. EPAM’s services have earned multiple Bio-IT World awards, as well as other awards for innovation in the Life Sciences. EPAM implements robust, scalable enterprise solutions designed with the user in mind and built by professionals who understand the science behind the software. Our solutions enable clients to speed research, discovery, and time-to-market while improving collaboration, knowledge management, and operational excellence. EPAM engages with challenging projects at a high level with flexible and scalable teams that understand our client’s priorities and use that understanding to deliver spectacular results.

Diagnostyka SA

Diagnostyka SA is a leading provider of medical diagnostic services in Poland, offering a wide range of laboratory tests and diagnostic imaging services. The company focuses on delivering high-quality diagnostic solutions to improve patient care and health outcomes. Diagnostyka SA is a premier medical diagnostics company in Poland, known for its wide range of laboratory and imaging services. They focus on high-quality diagnostics, offering services like genetic testing and comprehensive imaging. Their commitment to digital health includes online access to test results and advanced health informatics, contributing to improved patient care and health outcomes​.

onebiome Sp. z o.o.

Onebiome Sp. z o.o. is at the forefront of personalized healthcare, leveraging advanced microbiome analysis to support health optimization. Our services include comprehensive gut microbiome characterization using third-generation DNA sequencing and AI-driven data interpretation. By providing detailed dietary and lifestyle recommendations, Onebiome empowers individuals to take control of their health, enhancing their overall well-being. Our expertise in medical diagnostics and bioinformatics underscores their innovative approach to modern healthcare​.

Hellenic Digital Health Cluster

The Hellenic Digital Health Cluster - HDHC - was founded in March 2021 and is based in Athens, Greece. It is a dynamic initiative of the Foundation for Research and Technology – Hellas (FORTH) that aims to include Greece among the leading countries in the field of digital health internationally.

Health Cluster Portugal

Health Cluster Portugal (HCP) is a private non-profit association that currently brings together more than 220 members, including R&D institutions, universities, hospitals, organisations from civil society, and companies in the areas of pharmaceuticals, biotechnology, medical technologies, and services. Together, HCP and its members develop innovative projects in areas such as translational and Clinical Research, Smart Health, e-Health, Medical Devices, Medtech, Active and Healthy Ageing and Health Tourism, with the purpose of turning knowledge into new products and services that contribute to the improvement of human health and wellbeing, improve health solutions exportations and to make Portugal the right place to invest and build partnerships in Health. Health Portugal integrates, in a cross-cutting and aggregating way, the national health offer in its various verticals.

BioLAGO e.V

Company Description: BioLAGO e.V. is the largest cross-border health network in the four-country region of Lake Constance, encompassing Germany, Switzerland, Austria, and Liechtenstein. Established in 2007, BioLAGO connects businesses and scientific institutions to foster innovation in the healthcare sector. The network focuses on high-tech areas such as medical technology, diagnostics, bioinformatics, and pharmaceuticals, including personalized medicine. By promoting knowledge transfer and supporting the establishment of new companies, BioLAGO actively contributes to the advancement of regional healthcare.

HBio (Hellenic Bio Cluster)

HBio supports and promotes the Greek life sciences and healthcare ecosystem. We are proud to serve our members as well as stakeholders of the international community in working together to promote good science, commercial collaboration and sound business practices that lead to innovation and better health for all. The Hellenic BioCluster (HBio) is the first biosciences cluster in Greece bringing together the innovation leaders of Greece in the sectors of Pharmaceuticals, Biotechnology, Diagnostics, Medical Devices and Specialised Services. Established in 2006 by an initial group of 8 companies and the PRAXI Network, the technology transfer arm of the Foundation for Research & Technology- Hellas (FORTH), the Hellenic BioCluster has grown to date to over 30 innovation-intensive companies with an international outlook. HBio aims to boost the development of the Life Sciences industry in Greece, to promote the Greek Life Sciences sector in the international scene and to facilitate business and research collaborations between local and international companies and research groups. HBio is a frequent interlocutor of the Hellenic government on matters of policy design in the areas of innovation support and life sciences strategy. It is also an active member of the Σynergies initiative which seeks to promote intra-sectoral collaborations in the high tech space. As part of its support of the next generations, HBio is a sponsor of conferences and student competitions related to the life sciences, innovation and youth entrepreneurship.